Your browser doesn't support javascript.
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs.
Suzuki, Yuta; Ishihara, Hiroshi.
  • Suzuki Y; hhc Data Creation Center, Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan. Electronic address: y14-suzuki@hhc.eisai.co.jp.
  • Ishihara H; hhc Data Creation Center, Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan; Department of Formulation Science and Technology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
Drug Metab Pharmacokinet ; 41: 100424, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1458828
ABSTRACT
Nucleic acid therapeutics are developing into precise medicines that can manipulate specific genes. However, the development of safe and effective delivery system for the target cells has remained a challenge. Lipid nanoparticles (LNPs) have provided a revolutionary delivery system that can ensure multiple clinical translation of RNA-based candidates. In 2018, Patisiran (Onpattro) was first approved as an LNP-based siRNA drug. In 2020, during the coronavirus disease 2019 (COVID-19) outbreak, LNPs have enabled the development of two SARS-CoV-2 mRNA vaccines, Tozinameran (Comirnaty or Pfizer-BioNTech COVID-19 vaccine) and Elasomeran (Spikevax or COVID-19 vaccine Moderna) for conditional approval. Here, we reviewed the state-of-the-art LNP technology employed in three approved drugs (one siRNA-based and two mRNA-based drugs) and discussed the differences in their mode of action, formulation design, and biodistribution.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / RNA, Small Interfering / COVID-19 Vaccines / COVID-19 / MRNA Vaccines / Liposomes Type of study: Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Drug Metab Pharmacokinet Journal subject: Pharmacology / Metabolism Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / RNA, Small Interfering / COVID-19 Vaccines / COVID-19 / MRNA Vaccines / Liposomes Type of study: Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Drug Metab Pharmacokinet Journal subject: Pharmacology / Metabolism Year: 2021 Document Type: Article